Isolagen, Inc. Receives American Stock Exchange Notice Accepting Its Previously Submitted Plan of Compliance and Canceling the D
14 Agosto 2008 - 3:07PM
PR Newswire (US)
EXTON, Pa., Aug. 14 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc.
(AMEX:ILE) today announced that on August 14, 2008 it received
notice from the American Stock Exchange (AMEX) advising the Company
that its previously submitted plan of compliance demonstrates a
reasonable course of action by the Company to regain compliance
with AMEX's continued listing standards, and that the delisting
hearing previously scheduled for August 19, 2008 has been canceled.
AMEX indicated that its decision was based upon the information
disclosed in the Company's August 5, 2008 press release regarding
the positive top-line results from the Company's two pivotal, Phase
III clinical studies. The Company's previously submitted plan of
compliance outlined its strategy to regain its compliance with
AMEX's continued listing standards by September 14, 2009. About
Isolagen, Inc. Isolagen(TM), Inc. (AMEX:ILE) is an aesthetic and
therapeutic company committed to developing and commercializing
scientific advances and innovative technologies. The company's
technology platform includes the Isolagen Process(TM), a cell
processing system for skin and tissue rejuvenation which is
currently in clinical development for a broad range of aesthetic
and therapeutic applications including wrinkles, acne scars, burns
and periodontal disease. Isolagen also commercializes a
scientifically-advanced line of skincare systems through its
majority-owned subsidiary, Agera(R) Laboratories, Inc. For
additional information, please visit http://www.isolagen.com/.
Isolagen Forward Looking Statements All statements in this news
release that are not based on historical fact are "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995 and the provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
statements in this press release, include, without limitation, the
outcome of Amex's periodic review of the Company's plan of
compliance and Amex's willingness to permit continued listing
during the pendency of the plan. While management has based any
forward-looking statements contained herein on its current
expectations, the information on which such expectations were based
may change. These forward- looking statements rely on a number of
assumptions concerning future events and are subject to a number of
risks, uncertainties, and other factors, many of which are outside
of our control, that could cause actual results to materially
differ from such statements. Such risks, uncertainties, and other
factors include, but are not necessarily limited to, those set
forth under Item 1A "Risk Factors" in the Company's Annual Report
on Form 10-K for the year ended December 31, 2007, as updated in
"Item 1A. Risk Factors" in the Company's Quarterly Reports on Form
10-Q filed since the annual report. We operate in a highly
competitive and rapidly changing environment, thus new or
unforeseen risks may arise. Accordingly, investors should not place
any reliance on forward-looking statements as a prediction of
actual results. We disclaim any intention to, and undertake no
obligation to, update or revise any forward-looking statements.
Readers are also urged to carefully review and consider the other
various disclosures in the Company's Annual Report on Form 10-K for
the year ended December 31, 2007, as well as other public filings
with the SEC since such date. DATASOURCE: Isolagen, Inc. CONTACT:
Mike Beyer for Isolagen, Inc., +1-773-463-4211, Web site:
http://www.isolagen.com/
Copyright
Isolagen (AMEX:ILE)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Isolagen (AMEX:ILE)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Isolagen (American Stock Exchange): 0 recent articles
Más de Isolagen, Artículos de Noticias